Immucell Corp (ICCC): Revenue

Annual figures by period end, from SEC filings.

$27.64M
Year ended 2025-12-31
$30.68M
Trailing 12 months to 2026-06-30
+14.2%
3-year compound annual growth
+12.5%
5-year compound annual growth
2017-12-31: $10.43M2018-12-31: $10.99M2019-12-31: $13.72M2020-12-31: $15.34M2021-12-31: $19.24M2022-12-31: $18.57M2023-12-31: $17.47M2024-12-31: $26.49M2025-12-31: $27.64M$27.64M
2017-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$27.64M+4.3%2026-03-30, From 2025-01-01
2024-12-31$26.49M+51.6%2026-03-30, From 2024-01-01
2023-12-31$17.47M-5.9%2024-04-01, From 2023-01-01
2022-12-31$18.57M-3.5%2024-04-01, From 2022-01-01
2021-12-31$19.24M+25.4%2023-03-29, From 2021-01-01
2020-12-31$15.34M+11.8%2022-03-30, From 2020-01-01
2019-12-31$13.72M+24.9%2021-03-30, From 2019-01-01
2018-12-31$10.99M+5.3%2020-03-27, From 2018-01-01
2017-12-31$10.43Mn/a2019-03-22, From 2017-01-01

Revenue at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Immucell Corp (ICCC)2025-12-31$27.64M+4.3%
Alpha Teknova, Inc. (TKNO)2025-12-31$40.52M+7.4%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$67.67M+16.9%
Aspira Women's Health Inc. (AWHL)2025-12-31$9.22M+0.4%
Anbio Biotechnology (NNNN)2025-12-31$8.65M+5.6%
Biomerica Inc (BMRA)2026-05-31$4.45M-16.2%
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31$4.05M+115.6%
Volitionrx Ltd (VNRX)2025-12-31$1.73M+40.0%
Celldex Therapeutics, Inc. (CLDX)2025-12-31$1.54M-78.0%

Compare ICCC, TKNO, NTLA, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗